TBTheodore M. Brasky

Theodore M. Brasky

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Theodore M. Brasky has a total of 267 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Piloting cannabis for sleep disturbance in palliative care over 5 weeks: The pillow study protocol

    by Alison M. Newton, Jessica L. Krok-Schoen, Erin E. Stevens, Shanna L. Babalonis, Theodore L. Wagener, Alice Hinton, Roberto Benzo, Theodore M. Brasky

    Background: Sleep disturbance affects 60% of cancer patients, 3-fold that of the general population, and is frequently driven by clinical characteristics, physical symptoms, and psychological distress. Sleep disturbance and other symptoms often exacerbate one another, leading to reduced health-related quality of life (HRQOL). Sleep is the most commonly reported reason for cannabis use among adults with cancer, yet clinical evidence supporting its use for symptom management remains limited. Objectives: This report describes a protocol for a pilot randomized trial designed to evaluate the safety and feasibility of a cannabis-based intervention and to explore its preliminary efficacy for sleep disturbance and HRQOL. Methods: This pilot parallel-arm randomized clinical trial will enroll 50 patients from the Ohio State University Comprehensive Cancer Center (OSUCCC; anticipated Fall 2026). Eligible participants will be new to the OSUCCC’s Palliative Care clinic and report at least moderate sleep disturbance. Participants will be randomized by sex and race strata to receive either usual care or a nightly oral cannabis gummy containing 5 mg Δ-9-tetrahydrocannabinol (THC) and 5 mg cannabidiol (CBD), taken 1 hour before bedtime for 30 days. Adverse events will be monitored throughout the study. Sleep, HRQOL, and related symptoms will be assessed using self-reported questionnaires, ecological momentary assessments, and actigraphy. Conclusions: Findings will provide critical safety, feasibility, and preliminary efficacy data to support a future large-scale, multisite trial targeting sleep disturbance and symptom palliation in cancer care.

  • Open Access

    Prevalence of cannabis and medication use by indices of residential urbanicity and deprivation among Ohio cancer patients

    by Theodore M. Brasky, Shieun Lee, Bella McBride, Alison M. Newton, Ryan D. Baltic, Theodore L. Wagener, Sara Conroy, John L. Hays, Erin E. Stevens, Anita Adib, et al.

    Purpose: There is increasing interest in the use of cannabis products to alleviate symptom burden among cancer patients. Although data remain limited, some evidence suggests that state legalization of cannabis is associated with reduced opioid use. Indices of area-level social determinants of health may provide insights into the patterns of symptom-managing behaviors in the context of health equity. Methods: Residential ZIP codes from 854 Ohio residents diagnosed with invasive cancer at an academic cancer center were used to assign rural–urban commuting area (RUCA) codes and social deprivation index (SDI) values. RUCA was categorized as metropolitan and non-metropolitan, and SDI was dichotomized at the median. Participants completed a one-time cannabis-focused questionnaire which included items on medications used to alleviate symptoms. Results: The prevalence of self-reported cannabis (19% vs. 13%) and opioid use (30% vs. 21%) were higher among patients living in areas of higher social disadvantage vs. lower. No differences were observed for use of benzodiazepines or for any product by residential urbanicity. Conclusion: Larger, multi-institutional studies with detailed measurement of cannabis and medications and an increased capacity to examine additional social determinants of health are needed to confirm and explain these descriptive findings.


  • Open Access

    Supplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative

    by Theodore M. Brasky, Leah R. Jager, Alison M. Newton, Xilin Li, Holli A. Loomans-Kropp, John L. Hays, Karen L. Margolis, Juhua Luo

    Supplemental Table 1, shows associations of NSAIDs/aspirin with pancreatic cancer risk by categories of smoking, alcohol, and body mass index.

  • Open Access

    Data from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative

    by Theodore M. Brasky, Leah R. Jager, Alison M. Newton, Xilin Li, Holli A. Loomans-Kropp, John L. Hays, Karen L. Margolis, Juhua Luo

    Background:Pancreatic cancer is among the most fatal human cancers and the fourth leading cause of cancer death in the United States. Evidence suggests that chronic inflammation may play a role in pancreatic carcinogenesis and its inhibition through nonsteroidal anti-inflammatory drugs (NSAID) may reduce pancreatic cancer incidence.Methods:We examined associations of total and individual NSAIDs with pancreatic cancer risk among postmenopausal women participating in the Women’s Health Initiative observational study and clinical trial cohorts. Among 117,452 women, aged 55 to 79 years, 727 incident pancreatic cancer cases were reported over 18 years of follow-up. Cox regression was used to estimate hazard ratio (HR) and 95% confidence interval (CI) for associations between NSAIDs and pancreatic cancer risk.Results:Relative to non-use, consistent use of any NSAID was inversely associated with pancreatic cancer risk (HR 0.71, 95% CI, 0.59–0.87), primarily driven by strong associations for aspirin use (HR 0.67, 95% CI, 0.52–0.86). Use of total or individual non-aspirin NSAIDs was not associated with pancreatic cancer. Upon stratified analysis, we observed stronger associations for NSAIDs among participants with prevalent diabetes (HR 0.28, 95% CI, 0.10–0.75) relative to those without (HR 0.75, 95% CI, 0.61–0.92; P-interaction = 0.03).Conclusions:Additional large prospective studies with careful measurement of NSAID type, dose, and frequency are needed to further investigate the possibility of added benefit among individuals diagnosed with diabetes.Impact:This study adds to existing evidence from prospective studies and clinical trials suggesting that use of aspirin may provide moderate benefit for pancreatic cancer prevention.

  • Open Access

    Data from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative

    by Theodore M. Brasky, Leah R. Jager, Alison M. Newton, Xilin Li, Holli A. Loomans-Kropp, John L. Hays, Karen L. Margolis, Juhua Luo

    Background:Pancreatic cancer is among the most fatal human cancers and the fourth leading cause of cancer death in the United States. Evidence suggests that chronic inflammation may play a role in pancreatic carcinogenesis and its inhibition through nonsteroidal anti-inflammatory drugs (NSAID) may reduce pancreatic cancer incidence.Methods:We examined associations of total and individual NSAIDs with pancreatic cancer risk among postmenopausal women participating in the Women’s Health Initiative observational study and clinical trial cohorts. Among 117,452 women, aged 55 to 79 years, 727 incident pancreatic cancer cases were reported over 18 years of follow-up. Cox regression was used to estimate hazard ratio (HR) and 95% confidence interval (CI) for associations between NSAIDs and pancreatic cancer risk.Results:Relative to non-use, consistent use of any NSAID was inversely associated with pancreatic cancer risk (HR 0.71, 95% CI, 0.59–0.87), primarily driven by strong associations for aspirin use (HR 0.67, 95% CI, 0.52–0.86). Use of total or individual non-aspirin NSAIDs was not associated with pancreatic cancer. Upon stratified analysis, we observed stronger associations for NSAIDs among participants with prevalent diabetes (HR 0.28, 95% CI, 0.10–0.75) relative to those without (HR 0.75, 95% CI, 0.61–0.92; P-interaction = 0.03).Conclusions:Additional large prospective studies with careful measurement of NSAID type, dose, and frequency are needed to further investigate the possibility of added benefit among individuals diagnosed with diabetes.Impact:This study adds to existing evidence from prospective studies and clinical trials suggesting that use of aspirin may provide moderate benefit for pancreatic cancer prevention.

  • Open Access

    Supplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative

    by Theodore M. Brasky, Leah R. Jager, Alison M. Newton, Xilin Li, Holli A. Loomans-Kropp, John L. Hays, Karen L. Margolis, Juhua Luo

    Supplemental Table 1, shows associations of NSAIDs/aspirin with pancreatic cancer risk by categories of smoking, alcohol, and body mass index.

  • Association of Diet Quality With Risk of Incident Rheumatoid Arthritis in the Women’s Health Initiative

    by Kanika Malani, Sushaili Pradhan, Mir Moafi Madani, Mary B. Roberts, Aladdin Shadyab, Matthew Allison, Theodore M. Brasky, Peter F. Schnatz, Linda Snetselaar, Charles B. Eaton


  • Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative

    by Theodore M. Brasky, Leah R. Jager, Alison M. Newton, Xilin Li, Holli A. Loomans-Kropp, John L. Hays, Karen L. Margolis, Juhua Luo

    Background: Pancreatic cancer is among the most fatal human cancers and the fourth leading cause of cancer death in the United States. Evidence suggests that chronic inflammation may play a role in pancreatic carcinogenesis and its inhibition through nonsteroidal anti-inflammatory drugs (NSAID) may reduce pancreatic cancer incidence. Methods: We examined associations of total and individual NSAIDs with pancreatic cancer risk among postmenopausal women participating in the Women’s Health Initiative observational study and clinical trial cohorts. Among 117,452 women, aged 55 to 79 years, 727 incident pancreatic cancer cases were reported over 18 years of follow-up. Cox regression was used to estimate hazard ratio (HR) and 95% confidence interval (CI) for associations between NSAIDs and pancreatic cancer risk. Results: Relative to non-use, consistent use of any NSAID was inversely associated with pancreatic cancer risk (HR 0.71, 95% CI, 0.59–0.87), primarily driven by strong associations for aspirin use (HR 0.67, 95% CI, 0.52–0.86). Use of total or individual non-aspirin NSAIDs was not associated with pancreatic cancer. Upon stratified analysis, we observed stronger associations for NSAIDs among participants with prevalent diabetes (HR 0.28, 95% CI, 0.10–0.75) relative to those without (HR 0.75, 95% CI, 0.61–0.92; P-interaction = 0.03). Conclusions: Additional large prospective studies with careful measurement of NSAID type, dose, and frequency are needed to further investigate the possibility of added benefit among individuals diagnosed with diabetes. Impact: This study adds to existing evidence from prospective studies and clinical trials suggesting that use of aspirin may provide moderate benefit for pancreatic cancer prevention.


  • Comment on Meta-Analysis Conducted by Li et al.

    by Theodore M. Brasky, Jill T. Brasky

    Dear Editors,We read with significant interest the recent paper by Li et al. (1), outlining results of their meta-analysis of published studies that examine associations of vitamin B6 (pyridoxine) ...

  • Open Access

    Which came first, the cannabis or the depression?

    by Theodore M. Brasky, Alison M. Newton, Jessica L. Krok-Schoen